id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-335576-b34nc3ay	Tsai, Andrew	Impact of tocilizumab administration on mortality in severe COVID-19	2020-11-05		.txt	text/plain	2917	180	44	Patients were stratified according to the receipt of tocilizumab for cytokine storm and matched to controls using propensity scores. The current analysis does not support the use of tocilizumab for the management of cytokine storm in patients with COVID-19. The objective of this analysis was to evaluate the clinical outcome of in-hospital mortality in patients with COVID-19 treated with tocilizumab in a single medical center. Subsequently, propensity score matching was performed to account for treatment strategy influenced by confounding by indication (the tendency of clinicians to prescribe tocilizumab in patients perceived to have cytokine storm and worsening trajectory). Currently Food and Drug Administration approved for use in the management of rheumatoid conditions and cytokine release storm-related to chimeric antigen receptor (CAR)-T cell therapy, tocilizumab has gained momentum as a potentially effective option in reducing IL-6 associated fevers and preventing clinical deterioration in COVID-19.	./cache/cord-335576-b34nc3ay.txt	./txt/cord-335576-b34nc3ay.txt